Eurofins Central Laboratory is pleased to announce that is has achieved an important strategic milestone with the expansion and relocation of its US Central Laboratory Operations
Eurofins Central Laboratory is pleased to announce that is has achieved an important strategicmilestone with the expansion and relocation of its U.S. Central Laboratory Operations to the330,000 square foot Eurofins Pharma Services campus in Lancaster, PA. The consolidation ofthe Central Laboratory into the Lancaster Laboratories campus, combined with the recentlyannounced acquisitions of leading bioanalytical, discovery, genomic and diagnostic laboratoriesin the US, positions Eurofins as a leading full service laboratory provider to the pharmaceuticaland biotech industries. This purpose built Central Laboratory is essential to the Eurofins CentralLaboratory global footprint of wholly-owned laboratory facilities in the United States, Europe,Asia and China.
Dr. Charles J. DiComo, Vice President & General Manager, U.S. & Global Laboratory Operations, explains: “The Central Laboratory in Lancaster is fully harmonized and seamlessly aligned with our other Eurofins Central Laboratories. All laboratory equipment, analytical methods, standard operating procedures and quality standards are identical across laboratories to support clinical trials being conducted across regions by our clients. Operating in line with both GLP and GCP standards, and with a strong expertise in biomarker analysis, we are positioning ourselves to become the first-choice Central Laboratory for our pharmaceuticalsponsors.”
Successfully operational since early April, the Eurofins Central Laboratory in Lancaster offers a full package of safety and esoteric testing. Furthermore, this location houses the Microbiology Center of Excellence for Eurofins Central Laboratory. The facility is accredited by thePennsylvania Department of Health, CAP, CLIA and NGSP Level I.
Elena Logan, Global Vice President Sales & Marketing, remarks: “The expansion of our Central Laboratory services on the Lancaster campus signifies the importance of this business within the portfolio of offerings of Eurofins Pharma Services. The Central Laboratory is core to the integration of our other laboratory services and as such, we continue to make significant investments in the business to ensure customers receive first class service and optimal delivery of results to support key decision making during and as a result of the clinical trials being run with Eurofins.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.